CHRS Q2 2020 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$136M+62.6% YoY

Gross Profit

$126M92.5% margin

Operating Income

$65M48.1% margin

Net Income

$59M43.5% margin

EPS (Diluted)

$0.70

QoQ Revenue Growth

+16.8%

Cash Flow

Operating Cash Flow

$60M

Free Cash Flow

$58M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$757M

Total Liabilities

$543M

Stockholders' Equity

$213M

Cash & Equivalents

$225M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$136M	$83M	+62.6%
Gross Profit	$126M	$83M	+51.6%
Operating Income	$65M	$27M	+137.6%
Net Income	$59M	$24M	+150.5%